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Abstract
The epithelial-mesenchymal transition (EMT) is an embryonic transdifferentiation process consisting of conversion of
polarized epithelial cells to motile mesenchymal ones. EMT–inducing transcription factors are aberrantly expressed in
multiple tumor types and are known to favor the metastatic dissemination process. Supporting oncogenic activity within
primary lesions, the TWIST and ZEB proteins can prevent cells from undergoing oncogene-induced senescence and
apoptosis by abolishing both p53- and RB-dependent pathways. Here we show that they also downregulate PP2A
phosphatase activity and efficiently cooperate with an oncogenic version of H-RAS in malignant transformation of human
mammary epithelial cells. Thus, by down-regulating crucial tumor suppressor functions, EMT inducers make cells particularly
prone to malignant conversion. Importantly, by analyzing transformed cells generated in vitro and by characterizing novel
transgenic mouse models, we further demonstrate that cooperation between an EMT inducer and an active form of RAS is
sufficient to trigger transformation of mammary epithelial cells into malignant cells exhibiting all the characteristic features
of claudin-low tumors, including low expression of tight and adherens junction genes, EMT traits, and stem cell–like
characteristics. Claudin-low tumors are believed to be the most primitive breast malignancies, having arisen through
transformation of an early epithelial precursor with inherent stemness properties and metaplastic features. Challenging this
prevailing view, we propose that these aggressive tumors arise from cells committed to luminal differentiation, through a
process driven by EMT inducers and combining malignant transformation and transdifferentiation.
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Introduction
While the disruption of embryonic processes has been
acknowledged as a cause of the outgrowth of paediatric neoplasms,
more recent observations suggest that the aberrant reactivation of
developmental regulatory programs might also contribute to
progression in the advanced stages of cancers in adults [1]. At
the crux of this concept is the subversion of the epithelial-
mesenchymal transition (EMT) during tumor progression. This
developmental program converts epithelial cells into mesenchymal
ones through profound disruption of cell-cell junctions, loss of
apical-basolateral polarity and extensive reorganization of the
actin cytoskeleton [2]. During embryogenesis, EMT plays critical
roles in the formation of the body plan and in the differentiation of
most of the tissues and organs derived from the mesoderm and the
endoderm [3]. This process is tightly regulated through a delicate
interplay between environmental signals from WNT, TGFb, FGF
family members, and a complex network of signaling pathways
that converge on the activation of transcription factors that induce
EMT through repression of CDH1 (encoding for the E-cadherin)
and activation of mesenchymal genes. EMT-inducing transcrip-
tion factors include several zinc finger proteins (e.g., SNAIL1,
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TWIST1, TWIST2 and E2A) and zinc-finger and homeodomain
proteins (ZEB1, ZEB2/SIP1) [4,5]. Importantly, while EMT
inducers are maintained in a silent state in adult differentiated
epithelial cells, their reactivation is commonly observed in a
variety of human cancers with a frequent correlation with poor
clinical outcome [6]. In the course of tumor progression, the gain
of cell motility and the secretion of matrix metalloproteases
associated with EMT promote cancer cell migration across the
basal membrane and invasion of the surrounding microenviron-
ment, favoring metastatic dissemination. Furthermore, EMT may
also facilitate second site colonization by endowing cells with stem-
like features including self-renewing properties [7–9]. While the
involvement of EMT inducers in the invasion-metastasis cascade
of epithelial tumors is well delineated, their contribution to
tumorigenesis remains unclear. Supporting an oncogenic activity
within primary lesions, we recently demonstrated that the TWIST
proteins were able to prevent cells from undergoing oncogene-
induced senescence and apoptosis by abrogating both p53- and
RB-dependent pathways [10,11]. As a consequence, TWIST1 and
TWIST2 can cooperate with an activated version of RAS to
transform mouse embryonic fibroblasts [11]. Furthermore, the
ZEB transcription factors were recently shown to overcome
EGFR-induced senescence in oesophageal epithelial cells, suggest-
ing that several EMT-inducers might share the property of
inhibiting oncogene-induced failsafe programs [12]. On the basis
of these findings, we sought to formally assess the oncogenic
activity of these EMT-promoting factors in the model of breast
tumorigenesis by generating Twist1 transgenic mouse models and
by performing cooperation assays in human mammary epithelial
cells (HMECs). The focus of this study was underpinned by the
common reactivation of ZEB1, ZEB2 and TWIST1 in aggressive
and undifferentiated human breast cancers, especially in the newly
identified claudin-low intrinsic subtype [13]. Here we demonstrate
that commitment to an EMT program favors breast tumor
initiation by inhibiting crucial tumor suppressor functions,
including PP2A (protein phosphatase 2A) activity, and thus
minimizes the number of events required for neoplastic transfor-
mation. Importantly, upon aberrant activation of an EMT
inducer, a single mitogenic activation is sufficient to transform
mammary epithelial cells into malignant cells exhibiting all the
characteristic features of claudin-low tumors. These findings
extend our understanding of the role of EMT-inducing transcrip-
tion factors during tumor development and highlight the claudin-
low tumor subtype of breast cancers as the first example of human
adult malignancies driven by aberrant reactivation of an
embryonic transdifferentiation program.
Results
TWIST1 expression promotes primary tumor
development in vivo
To gain insight into the role of EMT commitment in tumor
initiation and primary tumor growth, we used a Twist1 transgenic
mouse model exhibiting a lox-STOP-lox (LSL) version of the
active version of the murine TWIST1 (TWIST1-E12 tethered
dimer) under a ubiquitous promoter [14]. These mice were
crossed with a line expressing a lox-STOP-lox regulated knock-in
of the activated K-Ras oncogene (LSL-K-rasG12D) [15,16] for in
vivo oncogenic cooperation experiments. Transgene expression was
first induced using a Mouse Mammary Tumor Virus promoter
driven Cre recombinase (MMTV-Cre) and thereby restricted to
secretory tissues, in particular the mammary gland and skin
epithelia, as well as to the hematopoietic system [17,18]. Neither
wild-type nor MMTV-Cre;Twist1 mice exhibited tumor formation
by one year of age (n=47). Expression of knock-in K-rasG12D was
associated with low-grade splenic lymphomas as well as anal and
oral papillomas (Figure 1). Importantly, papillomas never
progressed to a malignant stage but could grow to the point to
physical obstruction leading to cachexia and requiring euthanasia
(n=85, median survival 85 days). In contrast, MMTV-Cre;K-
rasG12D;Twist1 mice invariably developed aggressive multifocal
squamous cell carcinomas (SCC) at very young ages necessitating
euthanasia at the significantly earlier median age of 35 days
(n=12, p,0.0001, Figure 1). These observations demonstrated for
the first time the oncogenic properties of TWIST1 in vivo and
underscored the cooperative effect between K-RAS and TWIST1
in promoting malignant conversion.
TWIST1 expression in murine differentiated mammary
epithelial cells promotes the development of claudin-low
breast cancers
Due to the speed with which SCC developed in the MMTV-
Cre;K-rasG12D;Twist1 animals, the role of TWIST1 in promoting
mammary tumor formation could not be assessed. Consequently,
transgene expression was next restricted to differentiated mam-
mary epithelial cells by using mice expressing the Cre recombinase
under the control of the Whey Acidic Protein promoter (WAP-
Cre) [17]. WAP is a milk protein expressed late in the
differentiation pathway of mammary epithelial cells [19]. The
2.6-kb fragment of the mouse WAP gene promoter used in the
present study is active in the mammary alveolar epithelium during
the second half of pregnancy upon the initiation of differentiation
[17,20]. In virgin animals, the promoter is only transiently
activated in a few mammary alveolar and ductal cells, during
estrus (average age at first estrus=35 days), allowing mosaic
transgene activation so as to better mimic the emergence of
spontaneous oncogenic activations [19]. Wild-type, WAP-Cre;K-
rasG12D, and WAP-Cre;Twist1 transgenic females exhibited
normal mammary gland development (Figure 2B) and remained
healthy for at least 240 days (n=19). However, all virgin WAP-
Cre;K-rasG12D;Twist1 females developed multifocal breast carci-
Author Summary
The epithelial-mesenchymal transition (EMT) is essential to
germ layer formation and cell migration in the early
vertebrate embryo. EMT is aberrantly reactivated under
pathological conditions, including fibrotic disease and
cancer progression. In the latter process, EMT is known to
promote invasion and metastatic dissemination of tumor
cells. EMT is orchestrated by a variety of embryonic
transcription factors called EMT inducers. Among these,
the TWIST and ZEB proteins are known to be frequently
reactivated during tumor development. We here report in
vitro and in vivo observations demonstrating that activa-
tion of these factors fosters cell transformation and
primary tumor growth by alleviating key oncosuppressive
mechanisms, thereby minimizing the number of events
required for acquisition of malignant properties. In a
model of breast cancer, cooperation between a single EMT
inducer and a single mitogenic oncoprotein is sufficient to
transform mammary epithelial cells into malignant cells
and to drive the development of aggressive and undiffer-
entiated tumors. Overall, these data underscore the
oncogenic role of embryonic transcription factors in
initiating the development of poor-prognosis neoplasms
by promoting both cell transformation and dedifferentia-
tion.
EMT Inducers as Early Drivers of Tumorigenesis
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transgene expression (p,0.001, median survival=125 days, n=9)
(Figure 2A and 2D). These tumors exhibited metaplastic features
with a mixed morphologic aspect that included epithelial-type and
spindle shaped cells (Figure 2D). In support of the relevance of
EMT in vivo, the presence of the tagged-TWIST1 transgene in
both the epithelial and fusiform cancer cell contingents demon-
strated that mesenchymal cells arose through transdifferentiation
of their epithelial counterparts (Figure 2D). Molecular character-
ization of human and murine breast tumors led to identifying five
intrinsic subtypes (luminal A, luminal B, HER2-enriched, basal-
like and claudin-low) [13,21,22]. Global gene expression profile
analysis (Accession number GSE32905) classified tumors devel-
oped by WAP-Cre;K-rasG12D;Twist1 transgenic mice as claudin-
low (Figure S1). Immunostaining of epithelial and mesenchymal
markers (Figure 2D) and quantitative RT-PCR analysis (lack of E-
cadherin and claudin expression, high expression of vimentin;
Figure S2) were highly consistent with this classification. Of note,
endogenous expression of the Zeb1, Zeb2 and Twist2 EMT
inducers was also induced (Figure S2), further supporting the
association of the EMT interactome with the claudin-low breast
cancer subtype [23].
TWIST1 and ZEB1/2 transcription factors foster malignant
transformation of human mammary epithelial cells and
provide cells with a basal-like or a claudin-low signature,
according to the extent of EMT
Both basal-like and claudin-low subgroups are aggressive,
chemoresistant, triple-negative carcinomas (estrogen-receptor-,
progesterone-receptor-, and HER2-negative). Yet claudin-low
tumors exhibit several characteristic features, including low
expression of adherens and tight junction proteins, a low level of
luminal/epithelial differentiation, stem cell-like features, and a
high frequency of metaplastic differentiation [24]. These tumors
are believed to originate from an early epithelial precursor with
inherent stemness properties and metaplastic features [24–26].
Nevertheless, the observation of claudin-low tumors in WAP-
Cre;K-RasG12D;Twist1 transgenic mice suggested that the devel-
opment of these neoplasms could rely upon an EMT-driven
Figure 1. Twist1 promotes tumor progression in vivo. Transgene expression was driven by the MMTV-Cre. While MMTV-Cre; Twist1 mice
(TWIST1; n=71) do not develop skin lesions, MMTV-Cre;K-rasG12D animals (RAS; n=89) spontaneously develop anal and oral papillomas. In MMTV-
Cre;K-rasG12D;Twist1 mice (RAS+TWIST1; n=19) papillomas evolve into squamous carcinomas. (A) HPS staining of skins either from K-rasG12D or K-
rasG12D;Twist1 transgenic mice. Transgene expression is induced by the MMTV-Cre. (B) Kaplan-Meier survival curves of transgenic mice. Survival
corresponds to the end point of the experiment, the tumor burden requiring euthanasia of the animal. Open circles indicate mice censored from the
dataset.
doi:10.1371/journal.pgen.1002723.g001
EMT Inducers as Early Drivers of Tumorigenesis
PLoS Genetics | www.plosgenetics.org 3 May 2012 | Volume 8 | Issue 5 | e1002723process affecting epithelial cells formerly engaged in differentia-
tion. We sought to test this hypothesis by mimicking in non-stem
cells events occurring commonly in this breast cancer subtype.
Claudin-low tumors and cell lines frequently exhibit increased
levels of the EMT-inducing transcription factors TWIST1, ZEB1,
and ZEB2 [13] and show activation of RAS/MAPK pathway
components [24,27]. To functionally reproduce these two
common features of claudin-low tumors, we performed oncogenic
cooperation assays by transducing genes encoding a single EMT
inducer (TWIST1, ZEB1 or ZEB2) and/or an active form of H-
RAS (H-RAS
G12V) into immortalized human mammary epithelial
cells (hTERT-HMECs, thereafter named HME cells). As in all
experiments the infection efficiency exceeded 80%, the hypothesis
of selection of a rare subpopulation of parental cells can be ruled
out. Forced expression of an EMT inducer triggered acquisition of
EMT features, including significant upregulation of mesenchymal
Figure 2. Twist1 promotes tumor initiation in vivo. Transgene expression was driven by WAP-Cre. While WAP-Cre;Twist1 (TWIST1; n=25) and
WAP-Cre;K-RasG12D (RAS; n=19) mice remained healthy, WAP-Cre;K-RasG12D;Twist1 females (RAS+TWIST1; n=21) developed metaplastic mammary
carcinomas. (A) Kaplan-Meier survival curves of transgenic mice. Survival corresponds to the end point of the experiment, the tumor burden requiring
euthanasia of the animal. Open circles indicate mice censored from the dataset. (B) HPS staining of mammary glands from either wild-type (wt),
Twist1 or K-rasG12D transgenic mice. (C) Expression analysis of ectopic TWIST1 in mammary glands of nulliparous WAP-Cre;Twist1 mice as assessed by
IHC shows that the WAP promoter is active in a few epithelial cells. (D) Characterization of the WAP-Cre;K-RasG12D;Twist1 mice-derived mammary
carcinomas (RAS+TWIST1). RAS and TWIST coexpression leads to the development of metaplastic carcinomas characterized by a predominant E-
cadherin
2, vimentin
+ fusiform contingent (tumors A, C, E, F) or the presence of two epithelial-like (E-cadherin
+) and fusiform (vimentin
+) cell
contingents (tumors B and D). For tumors B and D, both epithelial (upper panel) and fusiform (lower panel) cell contingents express the tagged-
TWIST1 transgenic protein, demonstrating that fusiform cells originate from the epithelial ones. Normal epithelial cells are arrowed.
doi:10.1371/journal.pgen.1002723.g002
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genes involved in epithelial cell-cell adhesion (i.e., E-cadherin,
occludin) (Figure 3). However, the degree of EMT commitment
observed after infection was highly dependent on the EMT-
inducing transcription factor, both in the absence or in the
presence of the active form of RAS. In the absence of the
mitogenic oncoprotein, ZEB1 expression was sufficient to promote
a complete transdifferentiation process, giving rise to typical
spindle-like cell morphology, and a total loss of E-cadherin
expression (Figure 3; HME-ZEB1 cells). In contrast, ZEB2-
expressing cells (HME-ZEB2 cells) and TWIST1-expressing cells
(HME-TWIST1 cells) exhibited intermediate phenotypes, main-
taining significant levels of E-cadherin expression and retaining a
cobblestone morphology despite increased levels of mesenchymal
markers such as vimentin and fibronectin (Figure 3). Transduction
of an active form of RAS further promoted EMT induction, as
assessed by cell morphology (Figure 3A) and protein expression
analysis (Figure 3F and 3G). Nevertheless, HME-ZEB2-RAS and
HME-TWIST1-RAS cells still exhibited an intermediate pheno-
type. Importantly, combining the mitogenic oncoprotein with
either TWIST1, ZEB1 or ZEB2 was sufficient to provide cells with
transformation potential, as assessed by their ability to form
colonies in an assay on semi-solid medium and by acquisition of a
characteristic stellate phenotype in 3D cell culture (Figure 3C and
3D). This observation suggested that EMT inducers could exert a
potent oncogenic activity in the absence of a complete EMT.
Global gene expression array analysis was next performed on
freshly established cell lines (Accession number GSE32905).
Strikingly, HME-ZEB1 cells and HME-ZEB1-RAS cells
were defined as basal-B (P=2.7610
220 and 2.4610
222 respec-
tively), reminiscent of claudin-low tumors [13,21], HME-
TWIST1, HME-TWIST1-RAS and HME-ZEB2 as basal-A
(P=3.6610
28, P=1.1610
22, P=3.8610
29 respectively), remi-
niscent of basal-like tumors [13,21], while HME-ZEB2-RAS
positively correlated with basal-A/basal-like (P=5.0610
22) and
basal-B/claudin-low (P=2.3610
22) (Figure 4 and Figure S3),
suggesting a direct link between the extent of EMT and the
intrinsic subtype. Confirming this hypothesis, exposure of HME-
TWIST1-RAS and HME-ZEB2-RAS to the EMT-promoting
cytokine TGFb triggered a complete EMT with a shift to basal-B/
claudin-low (P=2.3610
218 for TGFb-treated HME-TWIST1-
RAS cells; P=6.8610
222 for TGFb-treated HME-ZEB2-RAS
cells) (Figure 4 and Figure S3).
The extent of the EMT and the basal-B/claudin-low profiling
were strongly associated with acquisition of stem cell-like features,
as judged by the ability to form mammospheres under non-
adherent culture conditions (Figure 3E) and by the fraction of cells
exhibiting the CD44
+/CD24
2/low stem-like antigenic phenotype
(respectively 84.5%, 83.2%, 20.6% and 15.3% of HME-ZEB1;
HME-ZEB1-RAS, HME-ZEB2-RAS and HME-TWIST1-RAS;
Figure 5). The gain of a mammary stem cell signature was also
revealed by the use of the recently described Genomic Differen-
tiation Predictor [13], following global gene expression array
analysis on freshly established cell lines (Figure 6). Cells exhibiting
the more pronounced mesenchymal phenotype (HME-ZEB1,
HME-ZEB1-RAS; HME-ZEB2-RAS treated with TGFb and
HME-TWIST1-RAS treated with TGFb) exhibited a mammary
stem like signature, whereas cells with an epithelial or an
intermediate phenotype (HME, HME-TWIST1, HME-
TWIST1-RAS; HME-ZEB2; HME-ZEB2-RAS) showed a lumi-
nal progenitor signature.
As expected from earlier studies [28–30], immortalized HMEC
cells into which only H-RAS
G12V had been transduced (HME-
RAS) exhibited a low transformation potential (Figure 3D).
Characterization of the few colonies growing on soft agar revealed
a constant endogenous activation of EMT inducers, including
Figure 3. EMT induction by embryonic transcription factors facilitates HMEC transformation by an activated form of RAS.
Sequentially, HMECs were immortalized with hTERT (control) and infected with retroviral expression constructs for TWIST1, ZEB1, or ZEB2 and H-
RAS
G12V (as depicted on top). (A) Representative photomicrographs of cells obtained by phase contrast microscopy. (B) E-cadherin expression analysis
by immunofluorescence. (C) Cell morphology in 3D culture. (D) Transformation potential analysis by means of a soft agar colony formation assay.
Numbers of colonies are indicated 6 SD of three replicates. (E) Mammosphere formation assay under low adherence conditions. Numbers of
mammospheres per 20 000 cells are indicated 6 SD of three replicates. (F–G) Expression analysis of TWIST1, ZEB1, ZEB2, H-RAS, and of epithelial and
mesenchymal markers by western blotting. Quantification of E-cadherin, vimentin and fibronectin signals, normalized with respect to b-actin
expression and HMEC-hTERT-RAS derivatives is shown.
doi:10.1371/journal.pgen.1002723.g003
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phenotype, further highlighting the deleterious interplay between
the mitogenic oncoprotein and EMT-promoting factors. To
confirm the association between the RAS-induced transformation
and the endogenous expression of EMT inducers, immortalized
HMECs were transduced with an H-RAS
G12V and sorted by flow
Figure 4. Mesenchymal HMEC-derivatives display a claudin-low gene expression signature. (A) Statistical values of the Pearson’s
correlation to the centroids of intrinsic gene clusters determined according to the cell line gene expression data set of Neve and collaborators [21]. (B)
The expression of significative genes from the claudin-low signature [13,21] is shown. Relative transcript abundance with highest expression is
labeled in red and with lowest expression is labeled in green, respectively. MCF7 and MDA-MB157 were used as internal luminal and claudin-low
controls, respectively.
doi:10.1371/journal.pgen.1002723.g004
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epithelial cells were next cultured in the presence of TGFb.A s
shown in Figure S5, TGFb exposure triggered morphological and
phenotypical features of EMT, associated with increased expres-
sion of TWIST1, TWIST2, ZEB1 and ZEB2 EMT inducers.
Reactivation of these transcription factors was associated with the
acquisition of a transformed phenotype.
Taken together, these observations showed that activation of
EMT inducers, through either forced expression or endogenous
induction, fosters malignant transformation of mammary epithelial
Figure 5. Combined expression of H-RAS
G12V and EMT–inducing transcription factors provides HMEC cells with a stem cell–like
antigenic phenotype. Analysis by flow cytometry of the expression of CD44, CD24 (A) and EpCAM (B). Solid blue lines represent staining with FITC-
anti-EpCAM antibody and dotted red lines represent staining with FITC-conjugated isotype control. B.D.L.: Below Detection Limit. The claudin-low
mesenchymal breast cancer cell line MDA-MB231 was used as a negative EpCAM staining control.
doi:10.1371/journal.pgen.1002723.g005
Figure 6. Expression of EMT–inducing transcription factors triggers a dedifferentiation of HMEC cells. Mammary stem cells (MaSC),
luminal progenitor and luminal mature signatures of human cell line are defined according to Lim and collaborators [25], respectively. High scores are
indicative of a good correlation between the analyzed gene expression profiles and the established signatures. Cells lines with an epithelial
morphology are labeled in green while cell lines harboring a mesenchymal morphology are labeled in red.
doi:10.1371/journal.pgen.1002723.g006
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according to the extent of transdifferentiation.
EMT commitment triggers malignant transformation of
human mammary epithelial cells deficient for p53- and
RB-dependent pathways
Our data demonstrated that EMT inducers can promote
transformation of mammary epithelial cells. We and others have
previously shown that the TWIST and ZEB proteins can
functionally inhibit p53- and RB-dependent pathways, preventing
cells from undergoing oncogene-induced senescence and apoptosis
[10–12]. To test whether the oncogenic properties of EMT-
inducing transcription factors act only to lift these two oncosup-
pressive barriers or whether they might be involved in additional
processes, we have generated human mammary epithelial cells
deficient in both pathways. The INK4A tumor suppressor, a crucial
regulator of the RB-dependent pathway, is known to be silenced
by progressive promoter methylation in HMECs escaping from
stasis [31]. We depleted these cells of p53 by means of RNA
interference (using a shRNA TP53 thereafter named shp53 or, as a
control, a scrambled shRNA). Knockdown of p53 was checked by
western blotting and by demonstrating that, in response to DNA
damage, p53 induction and the resulting G1 growth arrest were
abolished (Figure S6). Cells were next infected with H-RAS
G12V
and immortalized by transfection with hTERT to generate shp53/
H-RAS
G12V/hTERT HMECs (hereafter named HME-shp53-
RAS cells). Characterization of the colonies generated after growth
of these cells in soft agar demonstrated that a vast majority of them
expressed mesenchymal markers (Figure S7E). This observation
led us to hypothesize that a subset of HME-shp53-RAS cells
committed spontaneously to an EMT program and that initiation
of the transdifferentiation process promoted cell transformation. In
support of the first hypothesis, cells exhibiting a cobblestone
phenotype and expressing epithelial markers (E-cadherin
+ and
EpCAM
+) and cells displaying a fibroblastic morphology and
exhibiting mesenchymal markers (vimentin
+) were found to coexist
in HME-shp53-RAS cells (Figure S7C). Epithelial and mesenchy-
mal cell subpopulations were next sorted on the basis of their
differential antigenic phenotypes (EpCAM
+ and EpCAM
2
respectively) (Figure S8). The phenotypes of the epithelial and
mesenchymal cell populations were confirmed by assessing the
expression of additional epithelial markers (b-catenin, E-cadherin,
ZO-1, and occludin) and mesenchymal markers (fibronectin and
vimentin) by immunofluorescence staining and western blotting
(Figure S9). The sorted mesenchymal-cell subpopulations specif-
ically displayed EMT-associated features such as motility, inva-
siveness, and a stellate phenotype when cultured in 3D (Figure 7).
Gene profile analysis classified these mesenchymal cells as claudin-
low/basal B, while epithelial HME-shp53-RAS cells were
classified as basal-like/basal A (Figure 4 and Figure S3). Although
epithelial and mesenchymal HMEC derivatives exhibited similar
H-RAS
G12V expression levels (Figure S10), only mesenchymal cells
grew in soft agar and gave rise to tumor formation, within three
months, when homotopically xenografted in nude mice (6 of 7
mice, Figure 7).
These observations demonstrated that EMT commitment
fosters malignant transformation of human mammary epithelial
cells deprived of functional p53- and RB-dependent pathways. To
further confirm this hypothesis sorted epithelial HME-shp53-RAS
cells were treated with TGFb. Exposure to this EMT-inducing
cytokine triggered a pronounced shift from epithelial to mesen-
chymal markers, associated with induction of ZEB1 (200-fold) and
ZEB2 (10-fold) (data not shown) and with a dramatic gain in
anchorage-independent growth properties (Figure S11). Impor-
tantly, forced expression of ZEB1 in sorted epithelial HME-shp53-
RAS cells was sufficient to mimic TGFb exposure, promoting both
EMT and cell transformation (Figure S12).
TWIST1 and ZEB1/2 transcription factors downregulate
the oncosuppressive PP2A activity
Our observations strongly suggested that, beyond the inhibition
of the p53- and RB-dependent pathways, EMT inducers display
additional, as yet unidentified oncogenic activities. It has been
previously shown that, in vitro, transformation of normal human
epithelial cells, including mammary epithelial cells, requires
disruption of the telomere maintenance system and dysregulation
of at least four key signaling pathways: activation of the RAS-
dependent pathway and inhibition of the p53-, RB-, and protein
phosphatase 2A-dependent pathways [28–30]. We thus endeav-
ored to analyze the effects of EMT commitment on protein
phosphatase 2A (PP2A) activity. PP2A is a ubiquitously expressed
serine/threonine phosphatase accounting, with protein phospha-
tase 1 (PP1), for 90% of all the serine/threonine phosphatase
activity in the cell [32]. By using a peptide substrate (synthetic
phosphothreonine peptide RRA(pT)VA) compatible with the
phosphatase activity of PP2A but not with that of PP1 and by
employing experimental conditions ensuring the specificity of
PP2A activity (see Materials and Methods), we found sorted
mesenchymal HME-shp53-RAS cells to exhibit lower phosphatase
activity than sorted epithelial HME-shp53-RAS cells (Figure 8).
More importantly, expression of either TWIST1, ZEB1, or ZEB2
in HME cells was sufficient to trigger significant (2-fold)
downregulation of serine/threonine phosphatase activity, reveal-
ing a novel oncogenic feature of these proteins. This downregu-
lation was similar to that observed in immortalized HMECs
transformed with H-RAS
V12 and the SV40 large T and small t
antigens (HMLER cells; Figure 8), the small t antigen being known
to inhibit PP2A activity [33]. Notably, claudin-low HME-ZEB1-
RAS cells exhibited 4-fold lower phosphatase activity than
immortalized HMECs (Figure 8).
Discussion
Whereas TWIST1 has been convincingly implicated in the
metastatic dissemination of breast cancer cells, these data
underscore the importance of EMT-inducing transcription factors
in driving mammary carcinogenesis, with a dual role in cell
transformation and dedifferentiation. Tumor development has
been portrayed as a multistep processes with a progressive
acquisition of genetic and epigenetic abnormalities providing cells
with biological capabilities such as sustained proliferation,
replicative immortality, survival advantages, angiogenesis and, in
some cases, invasive growth and metastasis [34]. According to the
Darwinian model of cancer development, each of these acquired
traits confers a distinct selective advantage, originating successive
waves of clonal expansion that drive tumor progression. It is well
known that this complex and time consuming process requires
abrogation of several oncosuppressive barriers. In epithelial cells,
including mammary epithelial cells, these barriers comprise the
p53-, RB- and PP2A-dependent pathways [28–30]. We and others
have previously demonstrated that TWIST and ZEB transcrip-
tions factors were capable to inhibit p53- and RB- dependent
pathways [10–12]. Remarkably, our observations reveal that
activation of these factors in HMECs also affects PP2A phospha-
tase activity. Considerable evidence highlights the tumor-suppres-
sor functions of this serine/threonine phosphatase. For example, it
has been shown in vitro that the transforming ability of the SV40
small t antigen requires interactions with PP2A and downregula-
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PLoS Genetics | www.plosgenetics.org 8 May 2012 | Volume 8 | Issue 5 | e1002723Figure 7. Characterization of epithelial and mesenchymal hTERT-shp53/RAS HMEC-derivative subpopulations. (A, B) Migratory and
invasive properties analyses as assessed by Boyden chamber migration and Matrigel invasion assays, respectively. (C) Cellular morphology in 3D
culture. (D) Transformation potential analysis assessed by a soft agar colony formation assay. Numbers of colonies are indicated 6 SD of triplicate
counting. (E) Tumorigenic potential analysis assessed by homotopically xenografts in nude mice. Numbers of mice developing tumors are indicated.
(F) Tumor histology: Hematoxylin-Phloxin Saffranin staining (HPS) and cytokeratin, E-cadherin and vimentin expression analysis assessed by
immunohistochemistry.
doi:10.1371/journal.pgen.1002723.g007
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components of the PP2A holoenzyme complex have been
identified in a variety of human malignancies and, in mouse
models, mutation of PP2A favors tumorigenesis [37]. Loss of PP2A
during cell transformation triggers multiple events, such as
upregulation of kinases involved in mitogenic and survival
signaling (e.g. AKT and MAPK), stabilization of protooncogenes
(e.g. MYC), destabilization of tumor suppressors (e.g. p53 and RB),
and loss of proapoptotic signaling pathways (e.g. BAD) [32].
Modulation of downstream components of the RAS signaling
pathway by PP2A might be of particular significance in our model,
as the ability of PP2A to antagonize the oncogenic properties of
RAS by dephosphorylating crucial downstream effectors such as c-
MYC and AKT makes its downregulation a prerequisite to RAS-
induced malignant transformation. The modulation of PP2A
activity by EMT inducers might thus be an important mechanism
underlying the deleterious cooperation of these factors with
oncogenic RAS in cell transformation. The inhibition of PP2A
activity by EMT inducers might also be relevant during
embryogenesis, as PP2A appears as a negative regulator of the
WNT signaling cascade [38] which is required for several crucial
steps in early development. Further studies are needed, however,
to better characterize the mechanisms involved in this regulatory
process, as PP2A represents a complex family of holoenzyme
complexes known to display different activities and to exhibit
diverse substrate specificities [39].
Given the importance of p53-, RB- and PP2A-dependent
protective barriers against tumorigenesis and their role in
regulating cell differentiation and self-renewal [40], aberrant
reactivation of EMT inducers might profoundly affect the
multistep nature of tumorigenesis by increasing cell plasticity
and leapfrogging the mutation bottleneck toward tumor progres-
sion. This view is supported by our in vitro transformation assays
demonstrating that, upon a single mitogenic activation, forced
expression of either TWIST1 or ZEB1/2 is sufficient to trigger
malignant conversion of immortalized human mammary epithelial
cells (hTERT-HMECs). It is also consistent with the observed
rapid and repeated appearance of multifocal breast carcinomas in
WAP-Cre;K-rasG12D;Twist1 mice. It is further supported by the
work by Phuoc T. Tran and colleagues, who demonstrated in an
elegant inducible transgenic mouse model that TWIST1 overex-
pression accelerates K-RAS-induced lung tumorigenesis [41].
Several phenomena associated with tumor initiation, such as
inflammation [42], physical constrains (including hydrostatic
pressure, shear stress and tension forces) [43], abnormal activation
of signaling pathways such as those controlled by WNT, NOTCH,
or TGFb [4,44], and hyperactivation or RAS-ERK1/2 signaling
[45] are known to trigger expression of EMT-promoting factors
and could thus induce reactivation of these embryonic transcrip-
tion factors in early stages of tumor development, as previously
observed in animal models [46]. Moreover, beyond the deleterious
consequences of aberrant reactivation of EMT inducers in
differentiated or committed epithelial cells, the ability of EMT
inducers to inhibit key oncosuppressive pathways also implies that
embryonic or adult stem cells that normally express these factors
are particularly vulnerable to cell transformation.
Cooperation assays demonstrate that activation of EMT-
inducing transcription factors such as TWIST1 or ZEB2 is
sufficient to make cells highly prone to transformation, even in the
absence of a complete mesenchymal morphological shift. In line
with this view, immunohistochemical analysis of TWIST1 in
human non-invasive breast cancers (ductal carcinomas in situ,
DCIS) has revealed frequent overexpression of this EMT inducer
within the bulk of the primary lesion, while the cancer cells
maintain an epithelial phenotype (Figure S13). EMT is known to
be a highly dynamic process giving rise to a series of important
changes in cell phenotype, including loss of cell polarity, loss of
cell-cell adhesion structures, remodeling of the cytoskeleton, and
promotion of cell motility. As recently highlighted by Klymkowsky
and Savagner, although the term EMT is generally applied as if it
were a single conserved process, EMT-related processes can in fact
vary in degree from a transient loss of cell polarity to total
Figure 8. Assessment of PP2A activity in hTERT-HMEC derivatives. PP2A phosphatase activity was assessed and normalized with respect to
the parental hTERT-HMEC cells. Activities are expressed in arbitrary units 6 SD of triplicate experiments. hTERT-HMECs transduced with SV40 T/t
antigens and H-RAS
G12V (HMLER, [29]) were used as an internal positive control.
doi:10.1371/journal.pgen.1002723.g008
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with combined epithelial and mesenchymal characteristics has
previously been demonstrated in vivo, in both mouse models of
EMT and human tumors [48,49]. Especially, epithelial cells
coexpressing cytokeratins 5/19 and vimentin have been identified
by dual immunofluorescence labeling in claudin-low and basal-like
breast cancers, two breast cancer subtypes frequently exhibiting
overexpression of EMT-inducing transcription factors [13].
Overall, these observations strongly suggest that EMT-promoting
factors can exert oncogenic functions in cells retaining an epithelial
phenotype, in the total absence of morphological features of EMT,
and probably long before initiation of the invasion-metastasis
cascade.
Previous in vitro studies using human mammary epithelial cells
have revealed a link between EMT, malignant transformation,
and acquisition of stem cell properties. For example, the
transformation of HMECs by means of a combination of hTERT,
SV40 large T and small t antigens, and H-RAS
G12V (HMLER
cells) is associated with both mesenchymal and stem-like features
[7,8,50]. In the absence of oncogenic RAS, introduction of SV40
T and small t antigens and hTERT into mammosphere-derived
HMECs also generates malignant cells exhibiting EMT and stem-
like properties [51]. Recent reports further demonstrate in human
cancer cell lines that spontaneous EMT or TGFb/TNFa-
mediated EMT generates cells with a claudin-low phenotype
[52,53]. Yet the intrinsic role of EMT inducers was not addressed
in these studies. We highlight herein a dual role of these factors in
cell transformation and dedifferentiation. Remarkably, in the
context of a very few genetic events, the aberrant activation of an
EMT inducer can initiate mammary epithelial cell transformation
in vitro and in vivo and can drive the growth of undifferentiated
tumors exhibiting all the characteristic features of claudin-low
tumors, including a malignant phenotype, low expression of tight
and adherens junction genes, EMT traits, and stem-cell-like
characteristics.
The origin of the different intrinsic subtypes of human breast
cancer is a topic of contentious debate and remains ill defined.
Recent in vitro observations support the view that both luminal and
basal-like breast cancers derive from a common luminal progen-
itor cell, whereas claudin-low tumors, viewed as the most primitive
malignancies, originate from a stem/progenitor cell with inherent
stemness properties and metaplastic features [24–26]. Others
suggest that basal-like and claudin-low tumors arise from
transformation of a similar stem cell, but that the claudin-low
tumors stay arrested in an undifferentiated state, while basal-like
cancer cells divide asymmetrically and give off differentiated
progeny arresting at the luminal progenitor state [54]. Our
observations pave the way for an alternative model highlighting a
dynamic process orchestrated by the activity of EMT-inducing
transcription factors. According to this model, aberrant activation
of EMT inducers in committed cells (e.g. luminal progenitors)
might foster initiation of triple-negative breast tumors and confer
basal-like or claudin-low signatures, according to the extent of
transdifferentiation. Our model also implies that basal-like tumors
might progressively evolve towards a claudin-low phenotype
through completion of the EMT process. This view is supported
by the histopathology of human metaplastic breast tumors:
phenotypically, the acquisition of mesenchymal features can occur
at various stages of the disease [55], highlighting the dynamic role
of transdifferentiation during tumor development and pointing to
the interaction between cancer cells and the microenvironment as
a key determinant of tumor phenotype and behavior. It is
noteworthy that a model of murine claudin-low tumors has
recently been described, involving transplantation of p53-null
mammary tissues into the cleared fat pads of wild-type recipients
[56]. This observation is consistent with the role of p53 loss in
EMT induction [57–59] and with the spontaneous generation of
mesenchymal cells exhibiting a claudin-low phenotype in HME-
shp53-RAS cells. Yet in this model described by Herschkowitz and
colleagues, p53-null mouse mammary tumors fell into a variety of
molecular groups, also including luminal and basal-like subtypes
[56]. WAP-Cre;K-rasG12D;Twist1 mice thus appear as the first
mouse model consistently generating claudin-low tumors. These
transgenic mice might thus serve as valuable preclinical models for
testing both potential therapeutic agents targeting these aggressive
neoplasms and potential preventive agents.
Materials and Methods
Constructs and mouse strains
The TWIST1-E12 tethered heterodimer was generated by PCR
by fusing the human TWIST1 and E12 proteins using a G3-S2-G2-
S-G3-S-G3-S2-G2-S-G3-S-G polylinker as described in [60]. The
full-length murine HA-tagged ZEB1 and ZEB2 cDNAs were
cloned into the pBabe retroviral construct. The TP53 shRNA
(shp53) pRETRO SUPER expression construct has been
described in [61].
Animal maintenance and experiments were performed in a
specific pathogen free animal facility ‘‘AniCan’’ at the CRCL,
Lyon, France in accordance with the animal care guidelines of the
European Union and French laws and were validated by the local
Animal Ethic Evaluation Committee. The heterozygous knock-in
LSL-K-rasG12D mouse strain [16] was crossed with CAG-LSL-
(Myc)-Twist1 mice (FVB background) [14]. Both TWIST1
monomer and T1-E12 dimers were used producing similar results
[60]. K-rasG12D;Twist1 offspring were subsequently crossed with
mice carrying the Cre recombinase under the control of the
Mouse Mammary Tumor Virus or Whey Acidic Protein
promoters (MMTV-Cre (B6129F1 background) or WAP-Cre
(c57BL/6 background) [17]; purchased from the NCI-MMHCC.
Cre (wild type), Cre;K-rasG12D, Cre;Twist1, and Cre;K-
rasG12D;Twist1 virgin animals were maintained and monitored
at least weekly for tumor incidence. End points were determined
based on tumor diameter (.17 mm) or the sick appearance of an
animal. Tissues were harvested and either snap frozen in N2(l) or
immersed in formalin until pathological analysis. Genotyping of
genomic DNA from tails purified using the NucleoSpin Tissue kit
(Macherey-Nagel) was performed with primers described in
references [14,16,17] using REDTaq 26ReadyMix (Sigma).
Cell culture
Primary human mammary epithelial cells (HMECs) were
provided by Lonza. HMEC-derivatives were cultured in 1:1
Dulbecco’s Modified Eagle’s Medium (DMEM)/HAMF12 medi-
um (Invitrogen) complemented with 10% FBS (Cambrex), 100 U/
ml penicillin-streptomycin (Invitrogen), 2 mM L glutamine (In-
vitrogen), 10 ng/ml human epidermal growth factor (EGF)
(PromoCell), 0.5 mg/ml hydrocortisone (Sigma) and 10 mg/ml
insulin (Actrapid).
Three-dimensional cultures consisted in culturing 5610
3 cells/
well in 2% growth factor reduced Matrigel (BD Biosciences) on top
of a 100% matrigel layer. 20 days after seeding, cells were fixed in
3% paraformaldehyde (Sigma), permeabilized in 0.5% Triton
100X (Sigma) in PBS buffer for 10 min. After several washes in
PBS, cells were labeled with 1 mg/ml of TRITC-conjugated
Phalloı ¨din P1951 (Sigma) for 45 min. Following washes in PBS,
nuclei were stained with Hoechst 5 mg/ml for 10 min and
mounted with Fluoromount-G (SouthernBiotech).
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pore filter, single-cells were plated at a density of 10
5 cells/ml in
Corning 3261 ultra-low attachment culture dishes. Primary cell
spheres were enzymatically dissociated with 0.05% trypsinfor 15 min
at 37uC to obtain single-cell suspension. The ability to generate
mammospheres was defined after three consecutive passages.
Treatment with TGFb was performed with 2.5 ng/ml of the
recombinant cytokine (Peprotech) for a three week period.
Cell distribution was performed using the FITC-EpCAM VU-
1D9 (Stem Cell), the FITC-CD44 G44-26 (BD Pharmingen) and
the PE-CD24 ML5 (BD Pharmingen) monoclonal antibodies, the
FACScan Calibur (Becton Dickinson) and analyzed using the
FlowJo software.
Matrigel invasion assays
Matrigel (BD Biosciences) was added to the wells of an eight-well
Labtek chamber in a volume of 300 ml/well. A Matrigel plug of
about 1 mm diameter was removed. The holewas successively filled
with 10
5 cells and 100 ml of Matrigel. Appropriate growth medium
was added on top. Cultures were analyzed after 24 h (Figure 7) or
72 h (Figure S11). Areas of migration were visualized using an
Olympus IX50 (NA 0.075). Samples were performed in duplicate.
Transwell migration assay
5610
4 cells were placed in the upper chamber of an 8 mM
Transwells (BD Biosciences). 24 h later, chambers were washed
twice with PBS. The filter side of the upper chamber was cleaned
with a cotton swab. The membrane was next cut out of the insert.
Cells were fixed in methanol and stained with 5% Giemsa 30 min
at room temperature.
Retroviral infection
2610
6 Phoenix cells were transfected by calcium-phosphate
precipitation with 10 mg of retroviral expression vectors. 48 h post-
transfection, the supernatant was collected, filtered, supplemented
with 5 mg/ml of polybrene (Sigma) and combined with 10
6
targeted cells for 6 h. Cells were infected twice and selected 48 h
post-second infection with puromycin (0.5 mg/ml), neomycin
(100 mg/ml) or hygromycin (25 mg/ml).
Soft-agar colony formation assay
To measure anchorage-independent growth, cells were de-
tached with trypsin and resuspended in growth medium. Plates
were prepared with a coating of 0.75% low-melting agarose
(Lonza) in growth medium and then overlaid with a suspension of
cells in 0.45% low-melting agarose (5610
4 cells/well). Plates were
incubated for 3 weeks at 37uC and colonies were counted under
microscope. Experiments were performed in triplicate.
Mouse injection
Eight-week old female athymic Swiss nude mice (C. River
laboratories) were X-irradiated (4 Gy) prior to injection. Single cell
suspensions, (5610
6 HMEC derivatives resuspended in a PBS-
Matrigel (1/1) mixture) were injected into the fat pad of a
mammary gland. Tumor incidence was monitored up to 90 days
post-injection. Animals were allowed to form tumors up to 1.5 cm
in diameter, at which point animals were euthanized. Each tumor
was dissected, fixed in paraformaldehyde and processed for
histopathology examination.
Immunoblot analysis
Cells were washed twice with phosphate buffered saline (PBS)
containing CaCl2 and then lysed in a 100 mM NaCl, 1% NP40,
0.1% SDS, 50 mM Tris pH 8 RIPA buffer supplemented with a
complete protease inhibitor cocktail (Roche). Protein expression
was examined by western blot using anti-E-cadherin clone 36
(Becton Dickinson), anti-b-catenin clone 14 (Becton Dickinson),
anti-fibronectin clone 10 (Becton Dickinson), anti-vimentin clone
V9 (Dako), anti-N-cadherin clone 32 (Becton Dickinson), anti-
occludin clone OC-3F10 (Zymed Laboratories), anti-b-actin clone
AC-15 (Sigma), anti-HA clone 11 (BabCO), anti-TWIST
Twist2C1a (Abcam) monoclonal antibodies and a rabbit poly-
clonal anti-H-RAS clone C20 (Santa Cruz) for primary detection.
Horseradish peroxidase-conjugated rabbit anti-mouse and goat
anti-rabbit polyclonal antibodies (Dako) were used as secondary
antibodies. Western blots were revealed using an ECL detection
kit (Amersham) or a western-blotting Luminol reagent (Santa
Cruz).
Immunofluorescence
10
4 cells were seeded on 8-well Lab-TekII chamber slide, fixed
in 3% paraformaldehyde (Sigma) and permeabilized in 0.1%
Triton 100X (Sigma) in PBS buffer at room temperature for
10 min. The cells were then washed 3 times with PBS and
incubated with a blocking solution (10% horse serum in PBS). The
cells were then incubated with the anti-E-cadherin clone 36
(Becton Dickinson) or the anti-vimentin clone V9 (Dako) primary
antibodies overnight at 4uC. Phalloidin labeling was performed by
incubating cells with 1 mg/ml of TRITC-conjugated Phalloı ¨din
P1951 (Sigma) for 30 min. Following extensive washes in PBS,
nuclei were stained with Hoechst 5 mg/ml for 10 min and
mounted with Fluoromount-G (SouthernBiotech). All matched
samples were photographed (control and test) using an immuno-
fluorescence microscope (Leica) and identical exposure times.
Immunohistochemistry on murine tumors
The immunohistochemical study was performed on three
microns deparaffinized sections, using the avidin-biotin-peroxidase
complex technique (LSAB universal, Dako), after 15 min heat-
induced antigen retrieval in 10 mM citrate buffer, pH 6. The
primary anti-E-cadherin clone 36 diluted at 1/500 (Becton
Dickinson), anti-vimentin clone V9 diluted at 1/200 (Dako) and
anti-c-MYC A14 at 1/100 (Santa-Cruz Biotechnology) antibodies
were applied 60 min at room temperature.
Immunohistochemistry on xenograft tumors
Paraffin embedded tumors were serially sectioned at a thickness
of 4 mm. After deparaffinisation and rehydration, endogenous
peroxidases were blocked by incubating the slides in 5% hydrogen
peroxide in sterile water. For heat induced antigen retrieval, tissue
sections were boiled at 97uC for 40 min either in a 10 mM citrate
buffer pH 6 (when anti-cytokeratin and anti-vimentin antibodies
were used) or in buffer pH 7 (Dako) (for the anti-E-cadherin
antibody) clone 36 (BD Biosciences). Slides were then incubated
with the monoclonal pancytokeratin clone AE1/AE3, (Dako), the
polyclonal anti-vimentin SC7557 (Santa Cruz) or the monoclonal
anti-E-cadherin clone 36 (BD Biosciences) primary antibodies or a
non-immune serum used as a negative control, for 1 h at room
temperature. Slides were rinsed in phosphate buffered saline, and
then incubated with a biotinylated secondary antibody bound to a
streptavidin peroxidase conjugate (LSAB+ kit, Dako).
Microarray analysis
Microarray processing and data analysis as well as procedures to
classify human cell lines and mammary tumors are described in
detail in Text S1.
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Cells were lysed in a 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
2 mM EDTA, 1 mM EGTA, 0.3% CHAPS lysis buffer supple-
mented with a protease inhibitor cocktail (Roche) and cleared by
centrifugation. The PP2A activity was assessed using the ‘‘Serine/
Threonine Phosphatase Assay System’’ (Promega) according to the
manufacture instruction. Briefly, the cleared cell lysate was filtered
through a Sephadex G25 column to remove free phosphate.
Protein concentration was determined using the Bradford method.
5 mg of cell protein was incubated in presence of the RRA(pT)VA
substrate in a 250 mM imidazole pH 7.2, 1 mM EGTA, 2 mM
EDTA, 0.1% b-mercaptoethanol, 0.5 mg/ml BSA PP2A-specific
reaction buffer at 25uC for 30 min. After incubation with 50 mlo f
molybdate dye/additive at 25uC for 30 min, optical density was
measured at 620 nm. All determinations were performed in
triplicate and the absorbance of the reactions was corrected by
determining the absorbance of control reactions without phos-
phoprotein substrate. The PP2A activity was performed in
presence of absence of 5 nM of okadoic acid to confirm the
specificity of these reaction conditions. The amount of phosphate
released (pmol) was calculated from a standard curve (0–
2000 pmol) and was normalized with respect to HMEC-hTERT
cells.
Supporting Information
Figure S1 Mammary tumors developed by WAP-Cre;K-
rasG12D;Twist1 mice exhibit a claudin-low gene expression
signature. Gene expression profiles of WAP-Cre;K-rasG12D;Tw-
ist1-mouse derived tumors (A, B and C) and of two MMTV-Neu
tumor-derived murine luminal cell lines were compared. (A)
Statistical values of the Pearson’s correlation to the centroids of
intrinsic gene clusters are determined according to the 122
reference murine tumors ([13]). MMTV-Neu tumor-derived
luminal cell lines were used as control luminal cells. (B) The
expression of meaningful genes from the claudin-low signature
([13,21]) is shown. Relative transcript abundance with highest
expression is labeled in red and with lowest expression is labeled in
green, respectively.
(TIF)
Figure S2 Characterization of the RAS+TWIST1 transgenic
mouse-derived tumors. Expression analysis of Twist1/2, Zeb1/2,
Cdh1, Vim, Cdln3 and Cdln7 in murine luminal control tumors 1
and 2 and the WAP-Cre;K-rasG12D;Twist1 (named RAS+TWIST)
trangenic mouse derived tumors A to D, as assessed by Q-RT-
PCR. Gene expression was assessed using the Hprt1 housekeeping
gene as an internal control. The expression level was normalized
with respect to murine luminal control tumor 1.
(TIF)
Figure S3 Combined expression of H-RAS
G12V and EMT-
inducing transcription factors provides HMEC cells with a
claudin-low gene expression signature. Hierarchical cluster
analysis of the established HMEC-derived cell lines using the
intrinsic gene clusters determined according to the cell line gene
expression data set of Neve and collaborators [21]. The basal A/
basal-like cluster is labeled in green, the basal B/claudin-low
cluster is labeled in blue and the luminal cluster is labeled in red,
HMEC-derived cell lines are labeled in yellow.
(TIF)
Figure S4 Transformed hTERT/RAS HMEC cells display
EMT features. (A) Expression analysis of epithelial and mesen-
chymal markers in HMEC-hTERT cells, in HMEC-hTERT cells
transduced with H-RAS
G12V (HMEC-hTERT/RAS) and in 21
independent HMEC-hTERT/RAS transformed colonies ob-
tained in a soft-agar transformation assay. (B) mRNA expression
analysis of EMT-inducing transcription factors (ZEB1, ZEB2,
TWIST1 and TWIST2) as assessed by Q-RT-PCR in the ten
colonies still expressing a significant level of E-cadherin. EMT-
inducing transcription factor expression was assessed using the
HPRT1 housekeeping gene as an internal control. The expression
level was normalized with respect to HMEC-hTERT cells. E:
Epithelial, M: Mesenchymal.
(TIF)
Figure S5 The EMT-promoting cytokine TGFb cooperates with
H-RAS for malignant transformation of HMEC cells. As depicted
on top, HMEC cells were sequentially infected with H-RAS
G12V
and immortalized with hTERT. The EpCAM
+ epithelial cell
population was sorted out and treated with TGFb (2.5 ng/ml) for a
three weeks period. EpCAM
2 mesenchymal cells were sorted out.
The properties of the epithelial and mesenchymal isogenic cell lines
were next compared. The optional step is indicated with brackets.
(A)Upperpanels:representative photomicrographsofcellsobtained
by phase-contrast microscopy. Middle panels: E-cadherin and
vimentin expression analysis assessed by immunofluorescence.
Lower panels: soft agar colony formation assay. Numbers of
colonies are indicated 6 SD of three replicates. (B) Expression
analysis of epithelial and mesenchymal markers by western blotting.
(C) TWIST1/2 and ZEB1/2 endogenous expression as assessed by
Q-RT-PCR using the HPRT1 housekeeping gene as an internal
control. The expression level was normalized with respect to the
EpCAM
+ sorted out epithelial cells.
(TIF)
Figure S6 Confirmation of p53 pathway inactivation in p53-
depleted cells. Expression analysis of p53, as assessed by western
blotting (panels A and D) and immunohistochemistry (panels B
and E), in hTERT-shcontrol (shRNA scramble) and hTERT-
shp53 HMEC derivatives in response to DNA damage induction
by adriamycin (+Adriamycin, panels A to C) or after c-ray ionizing
radiation (c-IR, panels D to F). Expression in non-treated cells
(2Adriamycin or - c-IR) were used as controls. (Panels C and F)
Cell-cycle distribution analysis before treatment (0 h) or 8 h/32 h
post-treatment (8 h+,3 2h +). Cell cycle distribution in absence of
treatment (8 h2,3 2h 2) is shown. Percentages of cells distributed
in the different cell cycle phases are indicated.
(TIF)
Figure S7 In vitro transformation assay of primary human
mammary epithelial cells. HMEC cells were sequentially depleted
of p53 through RNA interference (shp53), infected or not with H-
RAS
G12V and immortalized by hTERT as depicted on top. The
optional step is indicated by brackets. (A) Representative
photomicrographs of cells obtained by phase contrast microscopy.
(B) Transformation potential analysis, assessed by a soft agar
colony formation assay. Numbers of colonies are indicated 6 SD
of triplicate experiments. (C) E-cadherin (TRITC), EpCAM
(FITC) and vimentin (FITC) expression analysis assessed by
immunofluorescence. (D) Cell distribution and antigenic pheno-
type analysis using the EpCAM antigen. (E) EMT marker
expression analysis in transformed colonies as assessed by western
blotting.
(TIF)
Figure S8 Separation of the epithelial and mesenchymal
subpopulations of the h-TERT-shp53/RAS HMEC derived
subpopulations. Cell morphology, cell distribution and the
antigenic EpCAM phenotype are shown.
(TIF)
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hTERT-shp53/RAS HMEC derived subpopulations. (A) Expres-
sion analysis of the epithelial E-cadherin and the mesenchymal
vimentin markers assessed by immunofluorescence in the sorted
cell subpopulations, as indicated. (B) Expression analysis of
epithelial and mesenchymal markers by western blotting.
(TIF)
Figure S10 The differential oncogenic potential of mesenchymal
and epithelial hTERT-shp53/RAS HMEC-derivatives does not
rely on distinct H-RAS
G12V expression level. Ectopic expression of
RAS in epithelial and transformed mesenchymal hTERT-shp53/
RAS cells was assessed by Q-RT-PCR using the 36B4 gene as an
internal control. The expression level was normalized with respect
to hTERT-shp53/RAS epithelial cells.
(TIF)
Figure S11 TGFb-driven EMT provides hTERT-shp53/RAS
HMEC cells with transformation potential, motility and invasive
properties. Sequentially, HMEC cells were depleted in p53 (shp53),
infected with H-RAS
G12V, and immortalized with hTERT. The
epithelial subpopulation (1) was sorted out by FACS (EpCAM
+
subpopulation) and treated with TGFb (2.5 ng/ml) for a three
weeks period. The resulting mesenchymal population (2) was sorted
out by FACS (EpCAM
2 subpopulation). Experimental steps are
schematized on top. Characterization of the epithelial and
mesenchymal h-TERT-shp53/RAS isogenic cell lines. (A) Cell
distributionbeforeandaftercell sorting.Percentages ofEpCAM
+or
EpCAM
2 cells are indicated. (B) Representative photomicrographs
of cells obtained by phase-contrast microscopy. (C) Soft agar colony
formation assay. Numbers of colonies are indicated 6 SD of
triplicate experiments. (D, E) Migratory and invasive properties
analyses as assessed by Boyden chamber migration and Matrigel
invasionassays, respectively.(F)Expression analysis ofepithelial and
mesenchymal markers by western blotting.
(TIF)
Figure S12 Transition from p53-depleted H-RAS
G12V-expressing
epithelial cells into mesenchymal cells following ectopic expression of
ZEB1 provides cells with a transformation potential. Ectopic
expression of ZEB1 in sorted epithelial hTERT-shp53/RAS HMEC
cells induced cell commitment to EMT, as indicated by the
morphological change (A) the assessment of E-cadherin and vimentin
expression by immunofluorescence (B) and the assessment of EMT
marker expression by western blotting (D), provides cells with a
transformation potential as assessed in a soft-agar colony assay (C).
(TIF)
Figure S13 TWIST1 expression in human breast in situ
carcinomas. (A) Immunohistochemical analysis of TWIST1
expression in the normal mammary gland. While TWIST1 is
not expressed in mammary epithelial cells (arrows 1), the protein is
detected in some stromal fibroblasts (arrows 2). (B) TWIST1
expression was analyzed by immunohistochemistry in 34 human
ductal carcinomas (DCIS) of the breast. Representative TWIST1
staining of independent samples is shown. TWIST1 protein was
detected in 18 of them. Remarkably, in 11 of these cases TWIST1
was homogenously expressed in the bulk of the lesion even while
cancer cells maintained an epithelial phenotype. Top panels:
positive samples harbouring a strong and homogenous staining,
Middle panels: positive samples harbouring a weak and/or
heterogenous staining, Lower panels: negative samples. (C)
Analysis of vimentin expression by immunohistochemistry in
TWIST1-positive DCIS. Among the 18 TWIST1-positive sam-
ples, 6 expressed significant levels of vimentin while maintaining
an epithelial phenotype. Arrows 1: vimentin positive epithelial
cells. Arrows 2: vimentin negative epithelial cells. Arrow 3: normal
myoepithelial cells expressing vimentin.
(TIF)
Text S1 Supplementary Materials and Methods. Text S1
includes details of procedures employed to perform the transcrip-
tional expression analysis, the microarray processing and analysis,
the analysis of the p53 pathway functionality, the flow cytometry
analysis, the immunochemistry on human samples and the
assessment of the ectopic H-RASG12V expression.
(DOC)
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